Structure-based design of a selective heparanase inhibitor as an antimetastatic agent

Keisuke Ishida, Go Hirai, Koji Murakami, Takayuki Teruya, Siro Simizu, Mikiko Sodeoka, Hiroyuki Osada

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Heparanase is an endo-β-D-glucuronidase that degrades heparan sulfate glycosaminoglycans in the extracellular matrix and the basement membrane and is well known to be involved in tumor cell invasion and angiogenesis. We have focused on heparanase as a target for antitumor agents, especially antimetastatic agents. (R)-3-hexadecanoyl-5-hydroxymethyltetronic acid (RK-682) was found to display an inhibitory activity against heparanase in our screening of natural sources. Because RK-682 has been reported to show inhibitory activities against several enzymes, we have tried to develop selective heparanase inhibitors using the method of rational drug design. Based on the structure of the heparanase/RK-682 complex, we speculated that selective inhibitory activity against heparanase could be acquired by arylalkylation, namely, by benzylation of the 4-position of RK-682. Among the rationally designed 4-alkyl-RK-682 derivatives, 4-benzyl-RK-682 has been found to possess a selective inhibitory activity for heparanase (IC50 for heparanase, 17 μmol/L; IC50 for other enzymes, >100 μmol/L). 4-Benzyl-RK-682 also inhibited the invasion and migration of human fibrosarcoma HT1080 cells (IC50 for invasion, 1.5 μmol/L; IC50 for migration, 3.0 μmol/L). On the other hand, RK-682 had no inhibitory effect on the invasion and migration of HT1080 cells at doses of up to 100 μmol/L.

Original languageEnglish
Pages (from-to)1069-1077
Number of pages9
JournalMolecular Cancer Therapeutics
Volume3
Issue number9
Publication statusPublished - 2004 Sep
Externally publishedYes

Fingerprint

Inhibitory Concentration 50
Heparitin Sulfate
heparanase
RK 682
Fibrosarcoma
Drug Design
Glucuronidase
Enzymes
Glycosaminoglycans
Basement Membrane
Antineoplastic Agents
Cell Movement
Extracellular Matrix
Acids
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Ishida, K., Hirai, G., Murakami, K., Teruya, T., Simizu, S., Sodeoka, M., & Osada, H. (2004). Structure-based design of a selective heparanase inhibitor as an antimetastatic agent. Molecular Cancer Therapeutics, 3(9), 1069-1077.

Structure-based design of a selective heparanase inhibitor as an antimetastatic agent. / Ishida, Keisuke; Hirai, Go; Murakami, Koji; Teruya, Takayuki; Simizu, Siro; Sodeoka, Mikiko; Osada, Hiroyuki.

In: Molecular Cancer Therapeutics, Vol. 3, No. 9, 09.2004, p. 1069-1077.

Research output: Contribution to journalArticle

Ishida, K, Hirai, G, Murakami, K, Teruya, T, Simizu, S, Sodeoka, M & Osada, H 2004, 'Structure-based design of a selective heparanase inhibitor as an antimetastatic agent', Molecular Cancer Therapeutics, vol. 3, no. 9, pp. 1069-1077.
Ishida K, Hirai G, Murakami K, Teruya T, Simizu S, Sodeoka M et al. Structure-based design of a selective heparanase inhibitor as an antimetastatic agent. Molecular Cancer Therapeutics. 2004 Sep;3(9):1069-1077.
Ishida, Keisuke ; Hirai, Go ; Murakami, Koji ; Teruya, Takayuki ; Simizu, Siro ; Sodeoka, Mikiko ; Osada, Hiroyuki. / Structure-based design of a selective heparanase inhibitor as an antimetastatic agent. In: Molecular Cancer Therapeutics. 2004 ; Vol. 3, No. 9. pp. 1069-1077.
@article{08173e072021477c996845e4b0439786,
title = "Structure-based design of a selective heparanase inhibitor as an antimetastatic agent",
abstract = "Heparanase is an endo-β-D-glucuronidase that degrades heparan sulfate glycosaminoglycans in the extracellular matrix and the basement membrane and is well known to be involved in tumor cell invasion and angiogenesis. We have focused on heparanase as a target for antitumor agents, especially antimetastatic agents. (R)-3-hexadecanoyl-5-hydroxymethyltetronic acid (RK-682) was found to display an inhibitory activity against heparanase in our screening of natural sources. Because RK-682 has been reported to show inhibitory activities against several enzymes, we have tried to develop selective heparanase inhibitors using the method of rational drug design. Based on the structure of the heparanase/RK-682 complex, we speculated that selective inhibitory activity against heparanase could be acquired by arylalkylation, namely, by benzylation of the 4-position of RK-682. Among the rationally designed 4-alkyl-RK-682 derivatives, 4-benzyl-RK-682 has been found to possess a selective inhibitory activity for heparanase (IC50 for heparanase, 17 μmol/L; IC50 for other enzymes, >100 μmol/L). 4-Benzyl-RK-682 also inhibited the invasion and migration of human fibrosarcoma HT1080 cells (IC50 for invasion, 1.5 μmol/L; IC50 for migration, 3.0 μmol/L). On the other hand, RK-682 had no inhibitory effect on the invasion and migration of HT1080 cells at doses of up to 100 μmol/L.",
author = "Keisuke Ishida and Go Hirai and Koji Murakami and Takayuki Teruya and Siro Simizu and Mikiko Sodeoka and Hiroyuki Osada",
year = "2004",
month = "9",
language = "English",
volume = "3",
pages = "1069--1077",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Structure-based design of a selective heparanase inhibitor as an antimetastatic agent

AU - Ishida, Keisuke

AU - Hirai, Go

AU - Murakami, Koji

AU - Teruya, Takayuki

AU - Simizu, Siro

AU - Sodeoka, Mikiko

AU - Osada, Hiroyuki

PY - 2004/9

Y1 - 2004/9

N2 - Heparanase is an endo-β-D-glucuronidase that degrades heparan sulfate glycosaminoglycans in the extracellular matrix and the basement membrane and is well known to be involved in tumor cell invasion and angiogenesis. We have focused on heparanase as a target for antitumor agents, especially antimetastatic agents. (R)-3-hexadecanoyl-5-hydroxymethyltetronic acid (RK-682) was found to display an inhibitory activity against heparanase in our screening of natural sources. Because RK-682 has been reported to show inhibitory activities against several enzymes, we have tried to develop selective heparanase inhibitors using the method of rational drug design. Based on the structure of the heparanase/RK-682 complex, we speculated that selective inhibitory activity against heparanase could be acquired by arylalkylation, namely, by benzylation of the 4-position of RK-682. Among the rationally designed 4-alkyl-RK-682 derivatives, 4-benzyl-RK-682 has been found to possess a selective inhibitory activity for heparanase (IC50 for heparanase, 17 μmol/L; IC50 for other enzymes, >100 μmol/L). 4-Benzyl-RK-682 also inhibited the invasion and migration of human fibrosarcoma HT1080 cells (IC50 for invasion, 1.5 μmol/L; IC50 for migration, 3.0 μmol/L). On the other hand, RK-682 had no inhibitory effect on the invasion and migration of HT1080 cells at doses of up to 100 μmol/L.

AB - Heparanase is an endo-β-D-glucuronidase that degrades heparan sulfate glycosaminoglycans in the extracellular matrix and the basement membrane and is well known to be involved in tumor cell invasion and angiogenesis. We have focused on heparanase as a target for antitumor agents, especially antimetastatic agents. (R)-3-hexadecanoyl-5-hydroxymethyltetronic acid (RK-682) was found to display an inhibitory activity against heparanase in our screening of natural sources. Because RK-682 has been reported to show inhibitory activities against several enzymes, we have tried to develop selective heparanase inhibitors using the method of rational drug design. Based on the structure of the heparanase/RK-682 complex, we speculated that selective inhibitory activity against heparanase could be acquired by arylalkylation, namely, by benzylation of the 4-position of RK-682. Among the rationally designed 4-alkyl-RK-682 derivatives, 4-benzyl-RK-682 has been found to possess a selective inhibitory activity for heparanase (IC50 for heparanase, 17 μmol/L; IC50 for other enzymes, >100 μmol/L). 4-Benzyl-RK-682 also inhibited the invasion and migration of human fibrosarcoma HT1080 cells (IC50 for invasion, 1.5 μmol/L; IC50 for migration, 3.0 μmol/L). On the other hand, RK-682 had no inhibitory effect on the invasion and migration of HT1080 cells at doses of up to 100 μmol/L.

UR - http://www.scopus.com/inward/record.url?scp=4143140258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143140258&partnerID=8YFLogxK

M3 - Article

C2 - 15367701

AN - SCOPUS:4143140258

VL - 3

SP - 1069

EP - 1077

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 9

ER -